New treatment options in the management of IBD - focus on colony stimulating factors.
Inflammatory bowel disease (IBD) is characterized by inflammation of the gastrointestinal tract, typically with a relapsing and remitting clinical course. The intestinal inflammation in IBD is controlled by a complex interplay of innate and adaptive immune mechanisms. Innate immunity comprises a set of distinct elements, which includes circulating cells such as neutrophils, monocytes, and resident intestinal immune cells (dendritic and Paneth cells), as well as intestinal epithelium and cellular products, including antimicrobial peptides such as defensins and cathelicidins. Different components of innate immunity in IBD have been suggested to be defective or impaired. The human granulocyte-macrophage colony-stimulating factor (GM-CSF) and the human granulocyte colony-stimulating factor (G-CSF) have emerged as potential tools for the modulation of intestinal inflammation and repair. The greatest evidence supporting the use of colony-stimulating factors in intestinal inflammation comes from studies conducted in active Crohn's disease (CD) patients treated with sargramostim and filgrastim, but evidence for its recommendation as treatment remains weak, as the majority of studies are open label, nonrandomized, and with a small number of patients.
Barahona-Garrido
Josué
J
Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias, Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Yamamoto-Furusho
Jesús K
JK
Inflamm Bowel Dis. 2008 Oct;14(10):1443-52
18421761
Ann N Y Acad Sci. 2006 Aug;1072:300-6
17057209
Gut. 2008 Jul;57(7):903-10
18305068
J Leukoc Biol. 2006 Apr;79(4):860-6
16461743
J Immunol. 2005 May 15;174(10):6518-23
15879155
J Clin Gastroenterol. 1997 Jun;24(4):253-6
9252852
J Interferon Cytokine Res. 2006 May;26(5):291-300
16689657
Lancet. 2002 Nov 9;360(9344):1478-80
12433518
Clin Exp Immunol. 1996 Dec;106(3):529-33
8973623
Dan Med Bull. 1986 Oct;33(5):222-8
3536336
Lancet. 2006 Feb 25;367(9511):668-78
16503465
Aliment Pharmacol Ther. 2006 Aug 15;24(4):651-60
16907898
World J Gastroenterol. 2006 Nov 14;12(42):6751-5
17106921
Gastroenterology. 1976 Mar;70(3):439-44
1248701
Gut. 2004 Nov;53(11):1658-64
15479689
N Engl J Med. 1992 Jun 18;326(25):1666-9
1375344
J Pathol. 2008 Jan;214(2):260-6
18161747
Gut. 1998 Jan;42(1):127-30
9505898
Inflamm Bowel Dis. 2008 Aug;14(8):1033-40
18383179
Lancet. 2005 May 21-27;365(9473):1794-6
15910952
J Gastroenterol Hepatol. 1999 Jan;14(1):46-53
10029277
Digestion. 2003;68(2-3):63-70
14581762
Gut. 1991 Apr;32(4):399-402
1851125
Lancet. 1976 Jul 31;2(7979):219-21
59239
Aliment Pharmacol Ther. 2005 Feb 15;21(4):391-400
15709989
N Engl J Med. 2005 May 26;352(21):2193-201
15917384
Eur J Gastroenterol Hepatol. 2003 Jun;15(6):627-34
12840673
Inflamm Bowel Dis. 2008 Jan;14(1):88-99
17932977
Scand J Gastroenterol. 1985 Nov;20(9):1151-6
4089525